Phase II study of taselisib (GDC-0032) plus fulvestrant in HER2-negative, hormone receptor-positive advanced breast cancer: Analysis by PIK3CA and ESR1 mutation status from circulating tumor DNA

被引：1
|
作者：
Dickler, M. N.
Saura, C.
Oliveira, M.
Richards, D. A.
Krop, I. E.
Cervantes, A.
Stout, T. J.
Jin, H.
Savage, H. M.
Wilson, T. R.
Baselga, J.
机构：
[1] Mem Sloan Kettering Canc Ctr, Mem Hosp, 1275 York Ave, New York, NY 10021 USA
[2] Vall Hebron Univ Hosp, Vall Hebron Inst Oncol, Barcelona, Spain
[3] US Oncol Res, The Woodlands, TX USA
[4] Dana Farber Canc Inst, Boston, MA USA
[5] Univ Valencia, Inst Hlth Res INCLIVA, Valencia, Spain
[6] Genentech Inc, San Francisco, CA 94080 USA
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.SABCS16-P6-12-01
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P6-12-01
引用
收藏
页数：2
相关论文
共 50 条
  • [41] A phase II study of pembrolizumab plus fulvestrant in hormone receptor positive, HER-2 negative advanced/metastatic breast cancer patients
    Chan, Nancy
    Moore, Dirk
    Tandra, Pavankumar
    Rana, Jatin
    Omene, Coral
    George, Mridula
    Krishnamurthy, Jairam
    Desai, Shruti
    Patel, Nayana
    Wang, Yue
    Bicomong, Marc
    Tan, Xiao-Wei
    Hirshfield, Kim
    Ganesan, Shridar
    Toppmeyer, Deborah
    CANCER RESEARCH, 2022, 82 (04)
  • [42] Buparlisib in combination with tamoxifen in pretreated patients with hormone receptor-positive, HER2-negative advanced breast cancer molecularly stratified for PIK3CA mutations and loss of PTEN expression
    Welt, Anja
    Wiesweg, Marcel
    Theurer, Sarah
    Abenhardt, Wolfgang
    Groschek, Matthias
    Mueller, Lothar
    Schroeder, Jan
    Tewes, Mitra
    Chiabudini, Marco
    Potthoff, Karin
    Bankfalvi, Agnes
    Marschner, Norbert
    Schuler, Martin
    Breitenbuecher, Frank
    CANCER MEDICINE, 2020, 9 (13): : 4527 - 4539
  • [43] PIK3CA testing in hormone receptor-positive/HER2-negative metastatic breast cancer: real-world data from Italian molecular pathology laboratories
    Pepe, Francesco
    Venetis, Konstantinos
    Cursano, Giulia
    Frascarelli, Chiara
    Pisapia, Pasquale
    Vacirca, Davide
    Scimone, Claudia
    Rappa, Alessandra
    Russo, Gianluca
    Mane, Eltjona
    Pagni, Fabio
    Castellano, Isabella
    Troncone, Giancarlo
    Angelis, Carmine De
    Curigliano, Giuseppe
    Guerini-Rocco, Elena
    Malapelle, Umberto
    Fusco, Nicola
    PHARMACOGENOMICS, 2024, 25 (03) : 161 - 169
  • [44] Phase III study of GDC-0077 or placebo (pbo) with palbociclib (P) plus fulvestrant (F) in patients (pts) with PIK3CA-mutant/hormone receptor-positive/HER2-negative locally advanced or metastatic breast cancer (HR+/HER2-LA/MBC)
    Turner, N.
    Jhaveri, K.
    Kalinsky, K.
    Loibl, S.
    Loi, S.
    Im, S-A.
    Saura, C.
    Schmid, P.
    Schutzman, J. L.
    Stout, T.
    Lei, G.
    Hutchinson, K. E.
    Thanopoulou, E.
    Juric, D.
    ANNALS OF ONCOLOGY, 2020, 31 : S391 - S392
  • [45] Alpelisib Efficacy in Hormone Receptor-Positive HER2-Negative PIK3CA-Mutant Advanced Breast Cancer Post-Everolimus Treatment
    Raphael, Ari
    Salmon-Divon, Mali
    Epstein, Jessica
    Zahavi, Tamar
    Sonnenblick, Amir
    Shachar, Shlomit S.
    GENES, 2022, 13 (10)
  • [46] Quantitative characterization of the effects of fulvestrant alone or in combination with taselisib (PI3Kinase inhibitor) on longitudinal tumor growth in patients with estrogen receptor-positive, HER2-negative, PIK3CA-mutant, advanced or metastatic breast cancer
    Moein, Anita
    Jin, Jin Y.
    Wright, Matthew R.
    Wong, Harvey
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2024, 94 (03) : 421 - 436
  • [47] Ribociclib plus endocrine therapy in hormone receptor-positive, HER2-negative advanced breast cancer: A pooled safety analysis
    Burris, H. A.
    Chan, A.
    Im, S-A
    Chia, S.
    Tripathy, D.
    Esteva, F. J.
    Campone, M.
    Bardia, A.
    Kong, O.
    Bao, W.
    Diaz-Padilla, I.
    Lorenc, K. Rodriguez
    Yardley, D. A.
    CANCER RESEARCH, 2019, 79 (04)
  • [48] LORELEI: A phase II randomized, double-blind study of neoadjuvant letrozole plus taselisib (GDC-0032) versus letrozole plus placebo in postmenopausal women with ER-positive/HER2-negative, early-stage breast cancer.
    De Azambuja, Evandro
    Saura, Cristina
    Oliveira, Mafalda
    Dubsky, Peter Christian
    Zardavas, Dimitrios
    Fesl, Christian
    Bardia, Aditya
    Lin, Ray
    Fredrickson, Jill O.
    Parmar, Hema
    Singel, Stina Mui
    Hsu, Jerry Y.
    Piccart-Gebhart, Martine J.
    Gnant, Michael
    Baselga, Jose
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [49] LORELEI: A Phase II randomized, double-blind study of neoadjuvant letrozole plus taselisib (GDC-0032) versus letrozole plus placebo in postmenopausal women with ER-positive/HER2-negative, early-stage breast cancer.
    Saura, Cristina
    De Azambuja, Evandro
    Oliveira, Mafalda
    Dubsky, Peter Christian
    Zardavas, Dimitrios
    Fesl, Christian
    Bardia, Aditya
    Soberino, Jesus
    Fornier, Monica N.
    Boer, Katalin
    Ng, Vivian
    Fredrickson, Jill O.
    Stout, Thomas
    Singel, Stina
    Hsu, Jerry Y.
    Piccart-Gebhart, Martine J.
    Baselga, Jose
    Gnant, Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [50] Observational study of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer
    Ottestad, Lars
    Fronth, Line
    Rajendiran, Sajitha
    Aksnes, Liv Hege
    Eikesdal, Hans Petter
    Blix, Egil Store
    Ewertz, Marianne
    ACTA ONCOLOGICA, 2019, 58 (03) : 385 - 387
12345